IRMD Stock Forecast 2025-2026
Distance to IRMD Price Targets
IRMD Price Momentum
10 Quality Stocks Worth Considering Now
Researching iRadimed (IRMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IRMD and similar high-potential opportunities.
Latest IRMD Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, IRMD has a bullish consensus with a median price target of $71.00 (ranging from $70.00 to $72.00). Currently trading at $53.13, the median forecast implies a 33.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Wittes at Roth MKM, projecting a 35.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IRMD Analyst Ratings
IRMD Price Target Range
Latest IRMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IRMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 14, 2025 | Roth MKM | Jason Wittes | Buy | Reiterates | $72.00 |
| Aug 2, 2024 | Roth MKM | Jason Wittes | Buy | Maintains | $60.00 |
| Apr 22, 2024 | Roth MKM | Jason Wittes | Buy | Reinstates | $65.00 |
| Aug 2, 2021 | Roth Capital | Scott Henry | Buy | Maintains | $36.00 |
| Jul 31, 2017 | Roth Capital | Buy | Upgrade | $0.00 | |
| Oct 5, 2016 | Roth Capital | Neutral | Downgrade | $0.00 | |
| Apr 4, 2016 | Roth Capital | Buy | Maintains | $25.00 | |
| Jun 16, 2015 | Roth Capital | Buy | Maintains | $23.00 | |
| Aug 11, 2014 | Roth Capital | Initiates | $0.00 |
Iridium Corporation (IRMD) Competitors
The following stocks are similar to iRadimed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iridium Corporation (IRMD) Financial Data
Iridium Corporation has a market capitalization of $670.47M with a P/E ratio of 35.2x. The company generates $73.24M in trailing twelve-month revenue with a 26.3% profit margin.
Revenue growth is +11.1% quarter-over-quarter, while maintaining an operating margin of +29.9% and return on equity of +24.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Iridium Corporation (IRMD) Business Model
About Iridium Corporation
Provides satellite-based mobile communication services.
Iridium Corporation generates revenue through its satellite communication services, primarily by offering a range of products such as satellite phones, broadband solutions, and IoT connectivity. The company serves various sectors including maritime, aviation, government, and emergency services, ensuring reliable communication in remote and disaster-prone areas where traditional infrastructure fails.
Iridium operates a network of 66 low earth orbit satellites, enabling comprehensive global coverage. Their focus on innovation positions them as a leader in satellite communications, helping users maintain connectivity in challenging environments.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
160
CEO
Mr. Roger E. Susi
Country
United States
IPO Year
2014
Website
www.iradimed.comIridium Corporation (IRMD) Latest News & Analysis
Latest News
IRadimed Corporation has achieved 14 consecutive quarters of record revenue and a small dividend. US sales rose 21%, while international sales fell due to competition from cheaper alternatives.
IRadimed's consistent revenue growth and limited competition in a niche market highlight resilience. However, international sales challenges could impact future earnings, influencing investment decisions.
Iradimed Corporation (NASDAQ: IRMD) will participate in the 37th Annual Roth Conference, as announced on March 10, 2025.
Participation in the Roth Conference can enhance IRADIMED's visibility, attract investor interest, and potentially drive stock performance through increased engagement and funding opportunities.
IRADIMED CORPORATION (NASDAQ: IRMD) will hold its Q4 2024 earnings conference call on February 13, 2025, at 11:00 AM ET with CEO Roger Susi and CFO John Glenn participating.
The earnings call will provide insights into IRADIMED's financial performance, guiding investor expectations and influencing stock price based on results and future outlook.
IRadimed (IRMD) Lags Q4 Earnings Estimates
2 months agoIRadimed (IRMD) reported Q3 earnings of $0.44 per share, below the Zacks Consensus Estimate of $0.45, but up from $0.39 per share year-over-year.
IRadimed's earnings miss signals potential concerns about growth momentum, which may impact investor confidence and stock performance. Year-over-year improvement could mitigate some worry.
Iradimed Corporation (NASDAQ: IRMD) will release its Q4 2024 financial results on February 13, 2025, before market open, followed by a conference call at 11:00 a.m. ET.
Iradimed's upcoming financial results and conference call may impact stock performance, offering insights into company health and future guidance, influencing investor sentiment and decisions.
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
3 months agoIradimed Corporation (NASDAQ: IRMD) reported preliminary unaudited revenue for Q4 and fiscal year 2024, focusing on MRI-compatible medical devices.
Iradimed's preliminary revenue report can indicate financial health and growth potential, influencing stock performance and investor sentiment in the medical device sector.
Frequently Asked Questions About IRMD Stock
What is Iridium Corporation's (IRMD) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Iridium Corporation (IRMD) has a median price target of $71.00. The highest price target is $72.00 and the lowest is $70.00.
Is IRMD stock a good investment in 2025?
According to current analyst ratings, IRMD has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $53.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IRMD stock?
Wall Street analysts predict IRMD stock could reach $71.00 in the next 12 months. This represents a 33.6% increase from the current price of $53.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iridium Corporation's business model?
Iridium Corporation generates revenue through its satellite communication services, primarily by offering a range of products such as satellite phones, broadband solutions, and IoT connectivity. The company serves various sectors including maritime, aviation, government, and emergency services, ensuring reliable communication in remote and disaster-prone areas where traditional infrastructure fails.
What is the highest forecasted price for IRMD Iridium Corporation?
The highest price target for IRMD is $72.00 from Jason Wittes at Roth MKM, which represents a 35.5% increase from the current price of $53.13.
What is the lowest forecasted price for IRMD Iridium Corporation?
The lowest price target for IRMD is $70.00 from at , which represents a 31.8% increase from the current price of $53.13.
What is the overall IRMD consensus from analysts for Iridium Corporation?
The overall analyst consensus for IRMD is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $71.00.
How accurate are IRMD stock price projections?
Stock price projections, including those for Iridium Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.